Rescula Articles

Regulatory briefs on vortioxetine, canagliflozin/metformin combo and Rescula

13 December 2012

Sucampo fails in Amitiza arbitration with Takeda

9 July 2012

Sucampto gains US Canada rights for Rescula

24 April 2009

Japan stock market week to Nov 24, 2008

24 November 2008

US sales decline hits Santen results

22 November 2004

Tokyo pharma stocks - week July 19

26 July 2004

Tokyo pharma stocks - week to July 5

12 July 2004

Fujisawa invests $8M in Sucampo Pharma

19 August 2002

Fujisawa sales soar in North America

12 November 2001

Fujisawa net income slides 10.4% as R&D investment increases

21 May 2001

Prograf driving Fujisawa sales

13 November 2000

CIBA Vision's Rescula gets US approval

4 August 2000

Fujisawa fiscal 1999 turnover driven by Prograf

24 May 2000

CIBA Vision files for Rescula in USA and EU

3 March 2000

Ueno files patent infringement case against P&U

11 October 1999

Xalatan approved in Japan

17 March 1999

Net Loss Plunges To $270 Million At Fujisawa

21 May 1998

Mixed Results From Japanese Drugmakers

12 November 1997

1st Half Decrease in Sales At Fujisawa

10 November 1997

Fujisawa Sees 31% Net Income Rise For FY1996

26 May 1997

Nonconsolidated Interims From Fujisawa

11 November 1996

Difficult Year For Fujisawa After SB Deal Terminated

3 June 1996

Fujisawa Net Down Though Operating Income Soars

29 May 1995

Fujisawa Launch For Rescula

24 October 1994

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end